<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03345290</url>
  </required_header>
  <id_info>
    <org_study_id>PSS2016/PACTEP-VERGER/VS</org_study_id>
    <nct_id>NCT03345290</nct_id>
  </id_info>
  <brief_title>Impact of the Central Blood Pressure Level in Cerebral Metabolic Aging: a 18F-FDG PET Study.</brief_title>
  <acronym>PACTEP</acronym>
  <official_title>Impact of the Central Blood Pressure Level in Cerebral Metabolic Aging: a 18F-FDG PET Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cerebral glycolytic metabolism can be quantified by quantitative analysis of&#xD;
      18F-Fluorodeoxyglucose (18F-FDG) Positron Emission Tomography (PET). This allows to identify&#xD;
      neurological diseases at an early stage of functional abnormalities, before any anatomical&#xD;
      lesions, and to differentiate them from the &quot;normal&quot; brain aging. Aging mainly leads to&#xD;
      atrophy with a decrease in cerebral metabolism in the prefrontal cortex, with consequent&#xD;
      deterioration of cognitive processes, in particular executive functions (5).&#xD;
&#xD;
      In a population of 92 &quot;control&quot; subjects, investigators have already quantified the&#xD;
      importance of the aging in frontal cortex hypometabolism. These patients were referred for a&#xD;
      18F-FDG PET in the follow-up of lymphoma considered to be in complete remission (PET without&#xD;
      cerebral step), without any chemoradiotherapy within 2 months and with normal&#xD;
      neuropsychological tests (Mini Mental State Examination, MMSE, Mini International&#xD;
      Neuropsychiatric Interview MINI and Frontal Assessment Battery FAB).&#xD;
&#xD;
      However, cerebral aging can be &quot;accelerated&quot; by vascular risk factors, including increased&#xD;
      central blood pressure, as investigators have recently reported in a pilot study involving&#xD;
      elderly patients. This central pressure, which is directly linked to the cerebral&#xD;
      micro-vascularization, can be easily measured by applanation tonometry. In this pilot study,&#xD;
      investigators showed that a central pulse pressure equal or greater than 50 mmHg was&#xD;
      associated with a significant frontal hypometabolism in elderly patients. This confirmed, at&#xD;
      a stage of pre-clinical remodeling, the worse prognostic significance for this criterion, as&#xD;
      reported in large epidemiological studies (increased risk of stroke and cardiac vascular&#xD;
      events).&#xD;
&#xD;
      However, it is not yet known whether the level of central blood pressure interfere with the&#xD;
      brain metabolism of younger subjects, especially with regard to aging observed throughout&#xD;
      life. If this hypothesis is confirmed, preventive therapeutic strategies for accelerated&#xD;
      aging, could thus integrate the monitoring of central pressure and cerebral metabolism.&#xD;
&#xD;
      The objective of this study is to determine, in a population of control subjects and on a&#xD;
      larger scale, the impact of central blood pressure on brain metabolic aging , by using&#xD;
      18F-FDG PET.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 31, 2018</start_date>
  <completion_date type="Anticipated">December 2, 2021</completion_date>
  <primary_completion_date type="Actual">October 6, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>volume of brain areas detected by quantitative analysis</measure>
    <time_frame>At inclusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>topography of brain areas detected by quantitative analysis</measure>
    <time_frame>At inclusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>central blood pressure</measure>
    <time_frame>At inclusion</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Aging Disorder</condition>
  <arm_group>
    <arm_group_label>Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects referred to a FDG PET scan (standard PET without cerebral step) without any oncologic setting. Patients will be included as following critera: 25% of subjects will have under 40 years old, 25% between 40 and 60 yeard old et 50% higher than 60 years old.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PET with a cerebral step</intervention_name>
    <description>Positron Emission Tomography with a cerebral step before to carry out the standard Position Emission Tomography</description>
    <arm_group_label>Subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Central blood pressure measurement</intervention_name>
    <description>Central blood pressure measurement</description>
    <arm_group_label>Subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Neurocognitive tests</intervention_name>
    <description>Mini Mental State Examination, MMSE, Mini International Neuropsychiatric Interview MINI and Frontal Assessment Batery FAB</description>
    <arm_group_label>Subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  &gt; 18 years old, with written informed consent,&#xD;
&#xD;
          -  Subjects referred for 18F-FDG PET in a non-oncological setting,&#xD;
&#xD;
          -  Absence of pregnancy or breastfeeding,&#xD;
&#xD;
          -  Lack of chemotherapy in the previous year and no cerebral radiotherapy.&#xD;
&#xD;
          -  No history of psychiatric or neurological pathology.&#xD;
&#xD;
          -  Absence of treatment with psychotropic action, and absence of corticosteroids.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  &quot;abnormal&quot; neuropsychological tests:&#xD;
&#xD;
               -  Mini Mental State Examination (MMSE) &lt;27,&#xD;
&#xD;
               -  Current major depressive episode on the Mini International Neuropsychologic&#xD;
                  Interview (MINI),&#xD;
&#xD;
               -  Frontal Assessment Battery (FAB) &lt;15.&#xD;
&#xD;
          -  18F-FDG PET examination showing ischemic, neurodegenerative, neoplastic or other brain&#xD;
             lesions (independent of a normal or accelerated aging process).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antoine Verger, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU Nancy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHRU Nancy</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 10, 2017</study_first_submitted>
  <study_first_submitted_qc>November 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2017</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aging</keyword>
  <keyword>Central pressure</keyword>
  <keyword>FDG PET</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

